People with Parkinson’s disease are significantly less likely than those without the neurodegenerative disorder to develop colorectal cancer, a type of cancer that begins in the final part of the digestive tract, a new meta-analysis suggests. In fact, the analysis showed that the risk of developing such cancer…
Nearly four of every 10 patients with Parkinson’s disease experience minor hallucinations, a new study from China estimates. Results suggest a link between minor hallucinations and Parkinson’s-related sleep problems. The study, “Prevalence and Risk Factors for Minor Hallucinations in Patients with Parkinson’s Disease,” was published in …
No differences in cognitive abilities were identified between men and women with Parkinson’s disease, according to a recent study. Although no tests were conducted, the researchers suggested the lack of cognitive differences between male and female patients, which is found in aging healthy individuals, may be due to the…
Mission Therapeutics has been awarded a Therapeutic Pipeline Program grant from the Michael J. Fox Foundation for Parkinson’s Research (MJFF) to advance development of its USP30 deubiquitylating enzyme (DUB) inhibitors for the treatment of familial Parkinson’s disease. The grant, worth about $500,000, will be used to test these inhibitors in animals that model…
A deep brain stimulation (DBS) protocol that targets specific sets of nerve cells, or neurons, in the brain produced long-lasting effects in a mouse model of Parkinson’s disease. The new protocol, which uses brief bursts of electrical stimulation, offered effects that lasted hours longer than those of conventional DBS. The study,…
The University of Michigan (U-M) will use a five-year, $11.7 million grant to reopen its Morris K. Udall Center of Excellence in Parkinson’s Disease Research, according to a university press release. The grant, from the National Institute of Neurological Diseases and Stroke (NINDS), will fund research on falls and…
A new research project seeks to better characterize the structural properties of alpha-synuclein, which researchers hope will lead to a better understanding of this protein’s toxic effects in Parkinson’s disease. One of the hallmark features of Parkinson’s is the formation of aggregates — “clumps” or “tangles” — of alpha-synuclein…
Treatment with zonisamide — an approved epilepsy medication — can reduce “off” time without worsening treatment side effects in people with Parkinson’s disease, a new analysis of Japanese clinical trial data shows. Notably, the use of zonisamide did not increase dyskinesia, the uncontrolled, involuntary movements common among…
The HealthWell Foundation has opened a fund to support people with Parkinson’s or other neurocognitive diseases in the U.S.  who also are being treated for psychosis. To be eligible, patients must have a psychosis diagnosis, be on Medicare, and have a household income up to 500% of the…
Two established Parkinson’s disease (PD) treatments — Gocovri (amantadine) and Osmolex ER (amantadine hydrochloride) — will move to Supernus’ Pharmaceuticals when it completes an agreement now in place for it to acquire Adamas Pharmaceutical. The $450 million agreement — $50 million of which is contingent upon certain…
Get regular updates to your inbox.